IL16 PRODUCTION IS A MECHANISM OF RESISTANCE TO BTK INHIBITORS AND TO R‐CHOP.

Autor:	Arribas, A., Napoli, S., Cascione, L., Sartori, G., Cannas, E., Tarantelli, C., Spriano, F., Gaudio, E., Zucchetto, A., Rossi, F. M., Rinaldi, A., Castro de Moura, M., Jovic, S., Pittau, R. Bordone, Stathis, A., Stussi, G., Gattei, V., Brown, J. R., Esteller, M., Zucca, E.
Předmět:	BRUTON tyrosine kinase DIFFUSE large B-cell lymphomas DNA copy number variations ANTINEOPLASTIC combined chemotherapy protocols MANTLE cell lymphoma
Zdroj:	Hematological Oncology; Jun2023 Supplement S2, Vol. 41, p188-189, 2p
Abstrakt:	The demonstration that IL16 blocking therapies recovered sensitivity to therapies can lead to novel therapeutic approaches to overcome resistance in lymphoma patients. IL16 PRODUCTION IS A MECHANISM OF RESISTANCE TO BTK INHIBITORS AND TO R-CHOP B Introduction: b Covalent and non-covalent BTK inhibitors (BTKi) are used or being explored for the treatment of patients with B-cell malignancies, such as marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL) of the activated B-cell type (ABC). [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text